Biotech Archives - Page 27 of 795

2 minute read

GSK Concealed Risk Associated With Discontinued Heart Burn Drug Zantac, Whistleblower Lawsuit Claims

May 21, 12:48 PM

Valisure sues GSK accusing the company of hiding cancer risks linked to Zantac, potentially defrauding the U.S. government. This follows Valisure's 2019 tests showing Zantac forms a carcinogen, prompting a whistleblower lawsuit seeking billions in damages.

GSK

1 minute read

RenovoRx Announces Publication Of Results Of Pre-Clinical Studies Support Efficacy And Drug Delivery Mechanism Potential Of The Co’s TAMP Therapy Platform To Improve Targeted Cancer Drug Treatment Delivery

By Benzinga Newsdesk

May 21, 9:36 AM

Data shows that the Trans-Arterial Micro-Perfusion (TAMP) platform increases intra-arterial pressure, improving drug delivery with 100-fold increase local tissue concentration of the therapyTAMP offers the potential to

RNXT

2 minute read

Eli Lilly Secures China Nod For Popular Weight Loss/Diabetes Drug Tirzepatide

By Vandana Singh

May 21, 9:36 AM

Eli Lilly's diabetes drug tirzepatide receives approval in China, intensifying competition with Novo Nordisk's Ozempic. This move signals a significant expansion in the Asian market, where GLP-1 agonists are poised to drive a $2 billion market by 2030.

LLY

1 minute read

MIRA Pharmaceuticals Discusses With Memorial Sloan Kettering To Collaborate On A Preclinical Cancer Pain Model Utilizing The Co’s Novel Oral Ketamine Analog

By Benzinga Newsdesk

May 21, 8:49 AM

Ketamir-2, the Company's novel oral ketamine analog in development, aims to provide a safe and effective alternative for managing cancer pain and associated depressionMIAMI, May 21, 2024 /PRNewswire/ -- MIRA

MIRA

1 minute read

Biodexa Pharmaceuticals Presents Phase 2 Clinical Trial Results Of Its Newly-Licensed eRapa In Familial Adenomatous Polyposis Scheduled For Presentation At The 2024 Digestive Disease Week Annual Meeting; Reports Overall 83% Non-Progression Rate At 6 Mo…

By Benzinga Newsdesk

May 21, 8:38 AM

Biodexa Pharmaceuticals PLC("Biodexa" or the "Company")Positive Statistically Significant Phase 2 Clinical Trial Results of Biodexa's Newly-licensed eRapa™ in Familial Adenomatous Polyposis (FAP) Scheduled for

BDRX

1 minute read

GSK’s Experimental Asthma Drug Reduces Severe Attacks, Phase 3 Trial Data Shows

By Vandana Singh

May 21, 8:31 AM

GSK announced results from phase 3 trials SWIFT-1 and SWIFT-2, showing depemokimab's efficacy and safety in reducing severe asthma exacerbations.

GSK

1 minute read

Vir Biotechnology’s SOLSTICE Data To Be Featured At The European Association For The Study Of The Liver Congress 2024

By Benzinga Newsdesk

May 21, 8:30 AM

Vir Biotechnology, Inc. (NASDAQ:VIR) today announced the EASL Congress has changed the Company's Phase 2 SOLSTICE hepatitis delta presentation from a late-breaker poster to an oral presentation. The SOLSTICE data will be

VIR

1 minute read

NewAmsterdam Pharma Presents New Clinical And Preclinical Data On Obicetrapib’s Impact On Key Risk Factors For Cardiovascular Disease At Upcoming Medical Meetings

By Benzinga Newsdesk

May 21, 8:25 AM

-- Presentations include new data from OCEAN, ROSE, and ROSE2 Phase 2 clinical trials, demonstrating obicetrapib's impact on key lipid and lipoprotein biomarkers -- -- On track to report topline data from Phase 3

NAMS

1 minute read

ChatGPT Parent Open AI Partners With Sanofi, Formation Bio To Boost AI-Driven Drug Development

By Vandana Singh

May 21, 8:24 AM

Sanofi collaborates with OpenAI and Formation Bio to enhance drug development. The partnership leverages proprietary data, advanced AI models, and engineering expertise to accelerate the biopharma lifecycle.

MRNA

1 minute read

Tonix Pharmaceuticals Reports Key Findings From Initial Phase Of EVERSANA Market Opportunity Analysis For Tonmya For The Management Of Fibromyalgia

By Benzinga Newsdesk

May 21, 8:14 AM

Tonmya is a potential new first-line, centrally acting non-opioid analgesic for the management of fibromyalgia, supported by statistically significant results from two Phase 3 trials Primary physician research found

TNXP